The Coming Access Fight The debate over whether to cover GLP-1s in Medicare is really a part of the much larger debate in drug policy about value: Are the drugs we take worth the prices we pay for them
Critics of GLP-1 therapies often portray those who use these medications as opting for an easy way out to achieve thinness, perpetuating longstanding biases like those historically associated with bariatric surgery (Heitmann, 2025)
Source: Medpagetoday GLP-1 Receptor Agonist Shortage: South African perspective While GLP-1 receptor agonist shortage in South Africa has not been systematically studied, observational evidence suggests that these medications are still difficult to obtain countrywide
You can stop abruptly without dangerous withdrawal effects, but tapering down is recommended to maintain weight loss longer
Common experiences include: Longer periods between meals without hunger Easier portion control Reduced food noise Better adherence to healthy eating habits This is often the stage where patients realize theyre eating less without feeling deprived
The most commonly cited range in off-label veterinary use is 2 to 10 mcg per kilogram of body weight per day